Laser Acupoints Stimulation on Xerostomia Related Chemoradiotherapy for Head and Neck Cancer Patients
Launched by CAIRO UNIVERSITY · Jun 12, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using a special type of laser treatment on certain points of the body (called acupoints) can help reduce dry mouth (xerostomia) in patients receiving chemotherapy and radiation therapy for head and neck cancer. Dry mouth is a common side effect during these treatments and can make eating, speaking, and swallowing difficult. The goal is to see if this laser stimulation can provide relief and improve quality of life during cancer treatment.
To take part, patients need to have head and neck cancer and be undergoing combined chemotherapy and radiation therapy. Their salivary glands (which produce saliva) must be intact and working, and they should be medically stable. People with a history of dry mouth before treatment, bleeding problems, or certain other health issues will not be eligible. If accepted, participants will receive laser treatment on specific acupoints and be closely monitored throughout their cancer therapy. This study has not started recruiting yet, but it aims to find new ways to help patients manage the uncomfortable side effects of their cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chemoradiation therapy
- • Carcinoma in the head and neck area (NPC)
- • Anatomically intact parotid and submandibular glands.
- • All patients will be clinically and medically stable when attending the study.
- Exclusion Criteria:
- • They had a history of xerostomia;
- • They had suspected or confirmed physical closure of salivary gland.
- • ducts on either side.
- • They had known bleeding disorders.
- • They Were taking heparin or warfarin.
- • They had contraindications for the use of acupuncture at any acupoints.
- • They had history of cerebrovascular accident or spinal cord injury.
- • They had taken any drug or herbal medicine in the past 30 days that could affect salivary function.
- • They were planning to, or ended up taking such a substance during the study.
- • Any therapy that may affect treatment.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Amal Mohamed Abd El Baky, PhD
Study Chair
Professor, Cairo university
Adel Mahmoud Attia, PhD
Study Director
Lecturer, Zagazig university
Doaa Atef Aly, PhD
Study Director
Lecturer, Cairo university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported